AngioDynamics Announces Presentation of Positive Safety, Efficacy Results from RAPID Outcomes Database
November 12 2020 - 9:00AM
Business Wire
Represents Largest Catheter Based
Thromboaspiration Study Completed to Date
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease, and oncology, announced the safety and
efficacy results from the Registry of AngioVac* System Procedures
In Detail (RAPID) database. Results were shared by principal
investigator John Moriarty, MD, FSIR, FSVM (Associate Professor of
Radiology and Medicine, Cardiology—UCLA Interventional Radiology,
David Geffen School of Medicine at UCLA), at the Vascular
Interventional Advances (VIVA) 2020 meeting.
The registry was designed to evaluate the patterns of use,
safety and efficacy of the AngioVac System in the bulk removal of
undesirable intravascular material. The registry enrolled 234
patients across 21 sites, surpassing its 200-patient enrollment
goal. Among enrolled patients, 48.3% had a mass in the right heart,
35.9% had caval thromboemboli, 8.5 % had catheter related thrombi,
1.7% had a pulmonary embolism** and 5.6% had a combination of the
above.
“RAPID represents the largest catheter based thromboaspiration
study completed to date, and we are pleased to share its positive
findings,” said Scott Centea, AngioDynamics Sr. Vice President and
General Manager, VIT/PAD. “A growing number of providers are
recognizing the AngioVac System as a critically important tool in
the treatment and removal of thrombi and emboli. The overwhelmingly
positive results from the RAPID Registry demonstrate that the
AngioVac System is appropriate for use by a wide range of providers
treating thrombus, clot and vegetations in both peripheral deep
vein thrombosis (DVT) and the right heart.”
Findings from the RAPID Registry have been accepted for
publication in the Journal of Vascular and Interventional
Radiology1.
The primary objective of the registry was to capture data on the
use of the AngioVac System for various anatomic locations. Greater
than 70% of clot/mass removal was achieved in a majority of the
patient population. Overall, the study confirmed the AngioVac
System to be versatile, safe and effective for the removal of
vascular thrombi and cardiac masses across a broad range of patient
populations.
“Our goal threshold was to remove over 70% of the clot, which we
felt was clinically relevant, and each of the three main groups—the
caval group, the right heart group, and the catheter associated
clot group—were associated with very high rates of clot removal,”
commented Dr. Moriarty. “In the first two years of the Registry,
there were more caval thrombectomies than right heart mass
procedures, and that flipped in the latter two years. If we were to
extrapolate our trajectory, we would say that close to 70% of all
procedures are being performed in the right heart. Additionally,
the AngioVac System was successfully tested by a number of
different practitioners, including cardiologists, EP cardiologists,
cardiac surgeons, vascular surgeons, and interventional
radiologists. Ultimately, the diversity of providers, combined with
the efficacy and safety results, demonstrates the unique and
versatile nature of the AngioVac System.”
Learn more about the AngioVac System at AngioVac.com.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare
providers for vascular access, peripheral vascular disease, and
oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems, vascular access products,
angiographic products and accessories, drainage products,
thrombolytic products and venous products. For more information,
visit www.angiodynamics.com.
*AngioDynamics, the AngioDynamics logo, and AngioVac are
trademarks and/or registered trademarks of AngioDynamics, Inc., an
affiliate or subsidiary. All other trademarks are property of their
respective owners.
**Indications for Use: The AngioVac Cannula is indicated for use
as a venous drainage cannula and for removal of fresh, soft thrombi
or emboli during extracorporeal bypass for up to 6 hours. The
AngioVac Circuit is indicated for use in procedures requiring
extracorporeal circulatory support for periods of up to six hours.
For important AngioVac Cannula risk information, visit
https://www.angiodynamics.com/about-us/risk-information/#bangiovaccann.
For important AngioVac Circuit risk information, visit
https://www.angiodynamics.com/about-us/risk-information/#cangiovac.
1. Moriarty et al, Endovascular removal of thrombus and right
heart masses using the AngioVac system. Results of 234 patients
from the prospective multicenter registry of AngioVac procedures in
detail (RAPID). JVIR. Accepted for publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201112005641/en/
Investor Relations Contact: AngioDynamics, Inc. Stephen
Trowbridge 518-795-1408 strowbridge@angiodynamics.com
Media Contact: AngioDynamics, Inc. Saleem Cheeks
518-795-1174 scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2023 to Apr 2024